Targeting tumors with small molecule peptides

Current Cancer Drug Targets

Volumn 16, Issue 6, 2016, Pages 489-508

  Cheetham, Andrew G ^a   Keith, Daniel ^a   Zhang, Pengcheng ^a   Lin, Ran ^a   Su, Hao ^a   Cui, Honggang ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; Ligands; Peptides; Tumor targeting

Indexed keywords

ANGIOPEPTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; ANTINEOPLASTIC AGENT; LIGAND; MOLECULAR LIBRARY; PEPTIDE;

BINDING AFFINITY; BLADDER CANCER; BREAST CANCER; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DNA TRANSCRIPTION; GENE OVEREXPRESSION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; LARYNX CARCINOMA; LIGAND BINDING; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; MOUTH CANCER; MYELOMA; NEOPLASM; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; STOMACH CANCER; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; DRUG DELIVERY SYSTEM; MOLECULAR LIBRARY; NEOPLASMS; PROCEDURES; THERAPEUTIC USE;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NEOPLASMS; PEPTIDES; SMALL MOLECULE LIBRARIES;

EID: 84978245810     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009616666151130214646     Document Type: Review

References (252)

1. Siegel, R.; Ma, J. M.; Zou, Z. H.; Jemal, A. Cancer statistics. CA-A Cancer J. Clin., 2014, 64, 9-29.
2. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674.
3. Gerlinger, M. et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N. Engl. J. Med., 2012, 366, 883-892.
4. Chambers, A. F.; Groom, A. C.; MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer, 2002, 2, 563-572.
5. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo; G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56, 185-229.
6. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6, 789-802.
7. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4, 253-265.
8. Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov., 2011, 10, 671-684.
9. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2, 750-763.
10. Liu, Y.; Yu, J.; Bitterman, A.; Giuliano, A.; Cabot, M. Antisense oligonucleotides targeting ceramide glycosylation overcome multidrug resistance in cancer cells. Eur. J. Cancer, 2002, 38, S142-S142.
11. Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2004, 56, 1649-1659.
12. Brigger, I.; Dubernet, C. and Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Advan. Drug Deliv. Rev., 2002, 54, 631-651.
13. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7, 771-782.
14. Matsumura, Y.; Maeda, H. A. New concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46, 6387-6392.
15. Jain, R. K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol., 2010, 7, 653-664.
16. Prabhakar, U.; Maeda, H.; Jain, R. K.; Sevick-Muraca, E. M.; Zamboni, W.; Farokhzad, O. C.; Barry, S. T.; Gabizon, A.; Grodzinski, P.; Blakey, D. C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res., 2013, 73, 2412-2417.
17. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advan. Drug Deliv. Rev., 2011, 63, 136-151.
18. Torchilin, V. P. Passive and active drug targeting: drug delivery to tumors as an example. Handbook Exp. Pharmacol., 2010, 3-53.
19. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advan. Drug Deliv. Rev., 2008, 60, 1615-1626.
20. Bareford, L. M.; Swaan, P. W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev., 2007, 59, 748-758.
21. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66, 6732-6740.
22. Choi, C. H. J.; Alabi, C. A.; Webster, P.; Davis, M. E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Nat. Acad. Sci. USA, 2010, 107, 1235-1240.
23. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344, 783-792.
24. Chaffer, C. L.; Brennan, J. P.; Slavin, J. L.; Blick, T.; Thompson, E. W.; Williams, E. D. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Res., 2006, 66, 11271-11278.
25. Feldmann, G.; Dhara, S.; Fendrich, V.; Bedja, D.; Beaty, R.; Mullendore, M.; Karikari, C.; Alvarez, H.; Iacobuzio-Donahue, C.; Jimeno, A.; Gabrielson, K. L.; Matsui, W.; Maitra, A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res., 2007, 67, 2187-2196.
26. Dunn, S. E.; Ehrlich, M.; Sharp, N. J.; Reiss, K.; Solomon, G.; Hawkins, R.; Baserga, R.; Barrett, J. C. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res., 1998, 58, 3353-3361.
27. Albanese, A.; Lam, A. K.; Sykes, E. A.; Rocheleau, J. V.; Chan, W. C. W. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat. Commun., 2013, 4, 2718.
28. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279, 377-380.
29. Ferrara, N.; Kerbel, R. S. Angiogenesis as a therapeutic target. Nature, 2005, 438, 967-974.
30. Carmeliet, P.; Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473, 298-307.
31. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature, 407, 249-257, (2000).
32. Strebhardt, K.; Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer, 2008, 8, 473-480.
33. Scott, A. M.; Wolchok, J. D.; Old, L. J. Antibody therapy of cancer. Nat. Rev. Cancer, 2012, 12, 278-287.
34. Hudziak, R. M.; Lewis, G. D.; Winget, M.; Fendly, B. M.; Shepard, H. M.; Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 1989, 9, 1165-1172.
35. Izumi, Y.; Xu, L.; di Tomaso, E.; Fukumura, D.; Jain, R. K. Tumor biology-Herceptin acts as an anti-angiogenic cocktail. Nature, 2002, 416, 279-280.
36. Aboud-Pirak, E.; Hurwitz, E.; Pirak, M. E.; Bellot, F.; Schlessinger, J.; Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Nat. Cancer Inst., 1988, 80, 1605-1611.
37. Perrotte, P.; Matsumoto, T.; Inoue, K.; Kuniyasu, H.; Eve, B. Y.; Hicklin, D. J.; Radinsky, R.; Dinney, C. P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 1999, 5, 257-265.
38. Nuti, M. Bellati, F.; Visconti, V.; Napoletano, C.; Domenici, L.; Caccetta, J.; Zizzari, I. G.; Ruscito, I.; Rahimi, H.; Benedetti-Panici, P.; Rughetti, A. immune effects of trastuzumab. J. Cancer, 2011, 2, 317-323.
39. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol., 2005, 23, 1137-1146.
40. Webber, M. J.; Berns, E. J.; Stupp, S. I. Supramolecular nanofibers of peptide amphiphiles for medicine. Israel J. Chem., 2013, 53, 530-554.
41. Stupp, S. I. Self-assembly and biomaterials. Nano Lett., 2010, 10, 4783-4786.
42. Pollaro, L.; Heinis, C. Strategies to prolong the plasma residence time of peptide drugs. Med. Chem. Comm., 2010, 1, 319-324.
43. Ruoslahti, E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Advan. Mat., 2012, 24, 3747-3756.
44. Teesalu, T.; Sugahara, K. N.; Ruoslahti, E. Mapping of vascular zip codes by phage display. Methods Enzymol., 2012, 503, 35-56.
45. Pasqualini, R.; Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature, 1996, 380, 364-366.
46. Winter, G.; Griffiths, A. D.; Hawkins, R. E.; Hoogenboom, H. R. Making antibodies by phage display technology. Ann. Rev. Immunol., 1994, 12, 433-455.
47. Ladner, R. C.; Sato, A. K.; Gorzelany, J.; de Souza, M. Phage display-derived peptides as a therapeutic alternatives to antibodies. Drug Discov. Today, 2004, 9, 525-529.
48. Saad, M.; Garbuzenko, O. B.; Ber, E.; Chandna, P.; Khandare, J. J.; Pozharov, V. P.; Minko, T. Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumorspecific treatment and imaging? J. Control. Release, 2008, 130, 107-114.
49. Pasqualini, R.; Moeller, B. J.; Arap, W. Leveraging molecular heterogeneity of the vascular endothelium for targeted drug delivery and imaging. Semin. Thrombosis Hemostasis, 2010, 36, 343-351.
50. Li, Z. J.; Cho, C. H. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J. Transl. Med., 2012, 10, S1.
51. Ruoslahti, E. RGD and other recognition sequences for integrins. Ann. Rev. Cell Develop. Biol., 12, 697-715.
52. Danhier, F.; Le Breton, A.; Preat, V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm., 2012, 9, 2961-2973.
53. Meyer, A.; Auemheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Design, 2006, 12, 2723-2747.
54. Chen, K.; Chen, X. Y. Integrin targeted delivery of chemotherapeutics. Theranostics, 2011, 1, 189-200.
55. Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J. RGDbased strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resis. Updates, 2005, 8, 381-402.
56. Liu, S. Radiolabeled cyclic RGD peptides as integrin alpha(v) beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem., 2009, 20, 2199-2213.
57. Thorpe, P. E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res., 2004, 10, 415-427.
58. Matsuo, A. L.; Tanaka, A. S.; Juliano, M. A.; Rodrigues, E. G.; Travassos, L. R. A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity. J. Mol. Med., 2010, 88, 1255-1264.
59. Matsuo, A. L.; Juliano, M. A.; Figueiredo, C. R.; Batista, W. L.; Tanaka, A. S.; Travassos, L. R. A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity. Mol. Cancer Res., 2011, 9, 1471-1478.
60. Lammers, T.; Aime, S.; Hennink, W. E.; Storm, G.; Kiessling, F. Theranostic nanomedicine. Acc. Chem. Res., 2011, 44, 1029-1038.
61. Chlenski, A.; Guerrero, L. J.; Peddinti, R.; Spitz, J. A.; Leonhardt, P. T.; Yang, Q.; Tian, Y.; Salwen, H. R.; Cohn, S. L. Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol. Cancer, 2010, 9, 138.
62. Hasselaar, P.; Sage, E. H. Sparc antagonizes the effect of basic fibroblast growth-factor on the migration of bovine aortic endothelial-cells. J. Cell. Biochem., 1992, 49, 272-283.
63. Stetlerstevenson, W. G.; Aznavoorian, S.; Liotta, L. A. Tumor-cell interactions with the extracellular-matrix during invasion and metastasis. Ann. Rev. Cell Biol., 1993, 9, 541-573.
64. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010, 141, 52-67.
65. Mueller, J.; Gaertner, F. C.; Blechert, B.; Janssen, K. P.; Essler, M. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol. Cancer Res., 2009, 7, 1078-1085.
66. Rundhaug, J. E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med., 2005, 9, 267-285.
67. Fang, J. M.; Shing, Y.; Wiederschain, D.; Yan, L.; Butterfield, C.; Jackson, G.; Harper, J.; Tamvakopoulos, G.; Moses, M. A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Nat. Acad. Sci. U. S. A., 97, 3884-3889.
68. Breiteneder-Geleff, S.; Soleiman, A.; Kowalski, H.; Horvat, R.; Amann, G.; Kriehuber, E.; Diem, K.; Weninger, W.; Tschachler, E.; Alitalo, K.; Kerjaschki, D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries-Podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol., 1999, 154, 385-394.
69. Banerji, S.; Ni, J.; Wang, S. X.; Clasper, S.; Su, J.; Tammi, R.; Jones, M.; Jackson, D. G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol., 1999, 144, 789-801.
70. Stacker, S. A.; Caesar, C.; Baldwin, M. E.; Thornton, G. E.; Williams, R. A.; Prevo, R.; Jackson, D. G.; Nishikawa, S.; Kubo, H.; Achen, M. G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med., 2001, 7, 186-191.
71. Laakkonen, P.; Akerman, M. E.; Biliran, H.; Yang, M.; Ferrer, F.; Karpanen, T.; Hoffman, R. M.; Ruoslahti, E. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Nat. Acad. Sci. U. S. A., 2004, 101, 9381-9386.
72. Fogal, V.; Zhang, L.; Krajewski, S.; Ruoslahti, E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res., 2008, 68, 7210-7218.
73. Teesalu, T.; Sugahara, K. N.; Kotamraju, V. R.; Ruoslahti, E. Cend rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Nat. Acad. Sci. U. S. A., 2009, 106, 16157-16162.
74. Teesalu, T.; Sugahara, K. N.; Ruoslahti, E. Tumor-penetrating peptides. Front. Oncol., 2013, 3, 216.
75. Wool-Lewis, R. J.; Bates, P. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function. J. Virol., 1999, 73, 1419-1426.
76. Sanchez, A. J.; Vincent, M. J.; Erickson, B. R.; Nichol, S. T. Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J. Virol., 2006, 80, 514-525.
77. Molloy, S. S.; Bresnahan, P. A.; Leppla, S. H.; Klimpel, K. R.; Thomas, G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J. Biol. Chem., 1992, 267, 16396-16402.
78. Tosteson, M. T.; Tosteson, D. C. The sting. melittin forms channels in lipid bilayers. Biophys. J., 1981, 36, 109-116.
79. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Girard, O. M.; Hanahan, D.; Mattrey, R. F.; Ruoslahti, E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell, 2009, 16, 510-520.
80. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Co-administration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 2010, 328, 1031-1035.
81. Alberici, L.; Roth, L.; Sugahara, K. N.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Bordignon, C.; Traversari, C.; Rizzardi, G. P.; Ruoslahti, E. De Novo design of a tumor-penetrating peptide. Cancer Res., 2013, 73, 804-812.
82. Goel, S.; Duda, D. G.; Xu, L.; Munn, L. L.; Boucher. Y.; Fukumura, D.; Jain, R. K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev., 2011, 91, 1071-1121.
83. Harris, A. L. Hypoxia-A key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2, 38-47.
84. Vaupel, P.; Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev., 2007, 26, 225-239.
85. Jang, S. H.; Wientjes, M. G.; Au, J. L. S. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J. Pharm. Exp. Therap., 2001, 296, 1035-1042.
86. Tannock, I. F.; Lee, C. M.; Tunggal, J. K.; Cowan, D. S. M.; Egorin, M. J. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res., 2002, 8, 878-884.
87. Koivunen, E.; Wang, B. C.; Ruoslahti, E. Phage libraries displaying cyclic-peptides with different ring sizes-ligand specificities of the Rgd-directed integrins. Bio-Technology, 1995, 13, 265-270.
88. Brown, K. C. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr. Pharm. Design, 2010, 16, 1040-1054.
89. Assa-Munt, N.; Jia, X.; Laakkonen, P.; Ruoslahti, E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochem., 2001, 40, 2373-2378.
90. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R. A.; Shapiro, L. H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000, 60, 722-727.
91. Burg, M. A.; Pasqualini, R.; Arap, W.; Ruoslahti, E.; Stallcup, W. B. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res., 1999, 59, 2869-2874.
92. Kennel, S. J.; Mirzadeh, S.; Hurst, G. B.; Foote, L. J.; Lankford, T. K.; Glowienka, K. A.; Chappell, L. L.; Kelso, J. R.; Davern, S. M.; Safavy, A.; Brechbiel, M. W. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl. Med. Biol., 2000, 27, 815-825.
93. Arap, W.; Haedicke, W.; Bernasconi, M.; Kain, R.; Rajotte, D.; Krajewski, S.; Ellerby, H. M.; Bredesen, D. E.; Pasqualini, R.; Ruoslahti, E. Targeting the prostate for destruction through a vascular address. Proc. Nat. Acad. Sci. U. S. A., 2002, 99, 1527-1531.
94. Essler, M.; Ruoslahti, E. Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Nat. Acad. Sci. U. S. A., 2002, 99, 2252-2257.
95. Binetruy-Tournaire, R.; Demangel, C.; Malavaud, B.; Vassy, R.; Rouyre, S.; Kraemer, M.; Plouet, J.; Derbin, C.; Perret, G.; Mazie, J. C. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J., 2000, 19, 1525-1533.
96. Bae, D. G.; Gho, Y. S.; Yoon, W. H.; Chae, C. B. Arginine-rich antivascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J. Biol. Chem., 2000, 275, 13588-13596.
97. Asai, T.; Nagatsuka, M.; Kuromi, K.; Yamakawa, S.; Kurohane, K.; Ogino, K.; Tanaka, M.; Taki, T.; Oku, N. Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels. FEBS Lett., 2002, 510, 206-210.
98. Koivunen, E.; Arap, W.; Valtanen, H.; Rainisalo, A.; Medina, O. P.; Heikkila, P.; Kantor, C.; Gahmberg, C. G.; Salo, T.; Konttinen, Y. T.; Sorsa, T.; Ruoslahti, E.; Pasqualini, R. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol., 1999, 17, 768-774.
99. Curnis, F.; Sacchi, A.; Gasparri, A.; Longhi, R.; Bachi, A.; Doglioni, C.; Bordignon, C.; Traversari, C.; Rizzardi, G. P.; Corti, A. Isoaspartate-glycine-arginine: A new tumor vasculaturetargeting motif. Cancer Res., 2008, 68, 7073-7082.
100. Mingozzi, M.; Dal Corso, A.; Marchini, M.; Guzzetti, I.; Civera, M.; Piarulli, U.; Arosio, D.; Belvisi, L.; Potenza, D.; Pignataro, L.; Gennari, C. Cyclic isoDGR peptidomimetics as low-nanomolar v3 integrin ligands. Chemistry, 2013, 19, 3563-3567.
101. Li, Z. J.; Wu, W. K.; Ng, S. S.; Yu, L.; Li, H. T.; Wong, C. C.; Wu, Y. C.; Zhang, L.; Ren, S. X.; Sun, X. G.; Chan, K. M.; Cho, C. H. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J. Control. Rel., 2010, 148, 292-302.
102. Hoffman, J. A.; Giraudo, E.; Singh, M.; Zhang, L.; Inoue, M.; Porkka, K.; Hanahan, D.; Ruoslahti, E. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell, 2003, 4, 383-391.
103. Joyce, J. A.; Laakkonen, P.; Bernasconi, M.; Bergers, G.; Ruoslahti, E.; Hanahan, D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 2003, 4, 393-403.
104. Renschler, M. F.; Bhatt, R. R.; Dower, W. J.; Levy, R. Synthetic peptide ligands of the antigen-binding receptor induce programmed cell-death in a human B-cell lymphoma. Proc. Nat. Acad. Sci. U. S. A., 1994, 91, 3623-3627.
105. Marchio, S.; Lahdenranta, J.; Schlingemann, R. O.; Valdembri, D.; Wesseling, P.; Arap, M. A.; Hajitou, A.; Ozawa, M. G.; Trepel, M.; Giordano, R. J.; Nanus, D. M.; Dijkman, H. B.; Oosterwijk, E.; Sidman, R. L.; Cooper, M. D.; Bussolino, F.; Pasqualini, R.; Arap, W. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell, 2004, 5, 151-162.
106. Hui, X. L.; Han, Y.; Liang, S.; Liu, Z.; Liu, J.; Hong, L.; Zhao, L.; He, L.; Cao, S.; Chen, B.; Yan, K.; Jin, B.; Chai, N.; Wang, J.; Wu, K.; Fan, D. Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J. Control. Release, 2008, 31, 86-93.
107. Lee, T. Y.; Lin, C. T.; Kuo, S. Y.; Chang, D. K. & Wu, H. C. Peptidemediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res., 2007, 67, 10958-10965.
108. Hatakeyama, S.; Sugihara, K.; Shibata, T. K.; Nakayama, J.; Akama, T. O.; Tamura, N.; Wong, S. M.; Bobkov, A. A.; Takano, Y.; Ohyama, C.; Fukuda, M.; Fukuda, M. N. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc. Nat. Acad. Sci. U. S. A., 2011, 108, 19587-19592.
109. Laakkonen, P.; Porkka, K.; Hoffman, J. A.; Ruoslahti, E. A. tumorhoming peptide with a targeting specificity related to lymphatic vessels. Nat. Med., 2002, 8, 751-755.
110. Laakkonen, P.; Zhang, L. L.; Ruoslahti, E. Peptide targeting of tumor lymph vessels. Lymp. Continuum Rev., 2008, 1131, 37-43.
111. Zhang, L. L.; Giraudo, E.; Hoffman, J. A.; Hanahan, D.; Ruoslahti, E. Lymphatic zip codes in premalignant lesions and tumors. Cancer Res., 2006, 66, 5696-5706.
112. Oflazoglu, E.; Kissler, K. M.; Sievers, E. L.; Grewal, I. S.; Gerber, H.-P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br. J. Haematol., 2008, 142, 69-73.
113. Katz, J.; Janik, J. E.; Younes, A. Brentuximab vedotin (SGN-35). Clin. Cancer Res., 2011, 17, 6428-6436.
114. Lewis Phillips, G. D. Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Blattler, W. A.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, SR.; Spencer, S. D.; Sliwkowski, M. X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res., 2008, 68, 9280-9290.
115. Firer, M. A.; Gellerman, G. Targeted drug delivery for cancer therapy: the other side of antibodies. J. Hematol. Oncol., 2012, 5, 70.
116. Harrison, G. S.; Wierman, M. E.; Nett, T. M.; Glode, L. M. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr. Relat. Cancer, 2004, 11, 725-748.
117. Halmos, G.; Arencibia, J. M.; Schally, A. V.; Davis, R.; Bostwick, D. G. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J. Urol., 2000, 163, 623-629.
118. Heidenreich, A.; Pfister, D.; Merseburger, A.; Bartsch, G.; Gwg-Crpc. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur. Urol., 2013, 64, 260-265.
119. Garcia, J. A.; Rini, B. I. Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead. Cancer, 2012, 118, 2583-2593.
120. Liu, S. V.; Liu, S. S.; Pinski, J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Exp. Opin. Invest. Drugs, 20, 769-778.
121. Schally, A. V.; Engel, J. B.; Emons, G.; Block, N. L.; Pinski, J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr. Drug Deliv., 2011, 8, 11-25.
122. Dharap, S. S.; Wang, Y.; Chandna, P.; Khandare, J. J.; Qiu, B.; Gunaseelan, S.; Sinko, P. J.; Stein, S.; Farmanfarmaian, A.; Minko, T. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Nat. Acad. Sci U. S. A., 2005, 102, 12962-12967.
123. Liu, S. V.; Tsao-Wei, D. D.; Xiong, S.; Groshen, S.; Dorff, T. B.; Quinn, D. I.; Tai, Y. C.; Engel, J.; Hawes, D.; Schally, A. V.; Pinski, J. K. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration-and taxane-resistant prostate cancer. Clin. Cancer Res., 2014, 20, 6277-6283.
124. Letsch, M.; Schally, A. V.; Szepeshazi, K.; Halmos, G.; Nagy, A. Preclinical evaluation of targeted cytotoxic luteinizing hormonereleasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin. Cancer Res., 2003, 9, 4505-4513.
125. Engel, J.; Emons, G.; Pinski, J.; Schally, A. V. AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Exp. Opin. Invest. Drugs, 2012, 21, 891-899.
126. Popovics, P.; Schally, A. V.; Szalontay, L.; Block, N. L.; Rick, F. G. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget., 2014, 5, 4567-4578.
127. Speelmans, G.; Staffhorst, R. W. H. M.; Dekruijff, B.; Dewolf, F. A. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma-membrane. Biochem., 1994, 33, 13761-13768.
128. Tai, W. Y.; Mahato, R.; Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release, 2010, 146, 264-275.
129. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human-breast cancer-correlation of relapse and survival with amplification of the Her-2 neu oncogenE. Science, 1987, 235, 177-182.
130. Alimandi, M.; Romano, A.; Curia, M. C.; Muraro, R.; Fedi, P.; Aaronson, S. A.; Di Fiore, P. P.; Kraus, M. H. Cooperative signaling of Erbb3 and Erbb2 in neoplastic transformation and human mammary carcinomas. Oncogene, 1995, 10, 1813-1821.
131. Yang, G.; Cai, K. Q.; Thompson-Lanza, J. A.; Bast, R. C.; Liu, J. S. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J. Biol. Chem., 2004, 279, 4339-4345.
132. Rubin, I.; Yarden, Y. The basic biology of HER2. Ann. Oncol., 2001, 12, S3-8.
133. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol., 2002, 20, 719-726.
134. Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharm., 2009, 157, 220-233.
135. Park, B. W.; Zhang, H. T.; Wu, C.; Berezov, A.; Zhang, X.; Dua, R.; Wang, Q.; Kao, G.; O'Rourke, D. M.; Greene, M. I.; Murali, R. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol., 2000, 18, 194-198.
136. Guillemard, V.; Nedev, H. N.; Berezov, A.; Murali, R.; Saragovi, H. U. HER2-Mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol., 2005, 24, 350-358.
137. Fantin, V. R.; Berardi, M. J.; Babbe, H.; Michelman, M. V.; Manning, C. M.; Leder, P. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res., 2005, 65, 6891-6900.
138. Witt, H., Hajdin, K., Iljin, K., Greiner, O., Niggli, F. K., Schafer, B. W., Bernasconi, M. Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1. Int. J. Cancer, 2009, 124(9), 2026-2032.
139. Wang, X. F.; Birringer, M.; Dong, L. F.; Veprek, P.; Low, P.; Swettenham, E.; Stantic, M.; Yuan, L. H.; Zobalova, R.; Wu, K.; Ledvina, M.; Ralph, S. J.; Neuzil, J. A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. Cancer Res., 2007, 67, 3337-3344.
140. Reichlin, S. Somatostatin 1. N. Engl. J. Med., 1983, 309, 1495-1501.
141. Patel, Y. C. Somatostatin and its receptor family. Front. Neuroendocrinol., 1999, 20, 157-198.
142. Volante, M.; Rosas, R.; Allia, E.; Granata, R.; Baragli, A.; Muccioli, G.; Papotti, M. Somatostatin, cortistatin and their receptors in tumours. Mol. Cell. Endocr., 2008, 286, 219-229.
143. Sun, L. C.; Coy, D. H. Somatostatin receptor-targeted anti-cancer therapy. Curr. Drug Deliv., 2011, 8, 2-10.
144. Shimon, I.; Yan, X.; Taylor, J. E.; Weiss, M. H.; Culler, M. D.; Melmed, S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas-Novel potential therapy for functional pituitary tumors. J. Clin. Invest., 1997, 100, 2386-2392.
145. Weckbecker, G.; Raulf, F.; Stolz, B.; Bruns, C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Therap., 1993, 60, 245-264.
146. Sideris, L.; Dube, P.; Rinke, A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist, 2012, 17, 747-755.
147. Schally, A. V.; Szepeshazi, K.; Nagy, A.; Comaru-Schally, A. M.; Halmos, G. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell. Mol. Life Sci., 2004, 61, 1042-1068.
148. Shen, H.; Hu, D.; Du, J.; Wang, X.; Liu, Y.; Wang, Y.; Wei, J. M.; Ma, D.; Wang, P.; Li, L. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. Eur. J. Pharmacol., 2008, 601, 23-29.
149. Li-Chun Sun, L. Vienna Mackey, Jing Luo, Joseph A. Fuselier & Coy, D. H. Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin. Med.: Oncol., 2008, 2, 491-499.
150. Kwekkeboom, D. J.; de Herder, W. W.; Kam, B. L.; van Eijck, C. H.; van Essen, M.; Kooij, P. P.; Feelders, R. A.; van Aken, M. O.; Krenning, E. P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26, 2124-2130.
151. Kwekkeboom, D. J.; Teunissen, J. J.; Bakker, W. H.; Kooij, P. P.; de Herder, W. W.; Feelders, R. A.; van Eijck, C. H.; Esser, J. P.; Kam, B. L.; Krenning, E. P. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol., 2005, 23, 2754-2762.
152. Eldar-Finkelman, H.; Eisenstein, M. Peptide inhibitors targeting protein kinases. Curr. Pharm. Design, 2009, 15, 2463-2470.
153. Nicolas, P. Multifunctional host defense peptides: intracellulartargeting antimicrobial peptides. FEBS J., 2009, 276, 6483-6496.
154. Aina, O. H.; Sroka, T. C.; Chen, M. L.; Lam, K. S. Therapeutic cancer targeting peptides. Biopolymers, 2002, 66, 184-199.
155. Buhl, L.; Szecsi, P. B.; Gisselo, G. G.; Schafer-Nielsen, C. Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia. Br. J. Haematol., 2002, 116, 549-554.
156. Fukuda, M. N.; Ohyama, C.; Lowitz, K.; Matsuo, O.; Pasqualini, R.; Ruoslahti, E.; Fukuda, M. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res., 2000, 60, 450-456.
157. McGuire, M. J.; Samli, K. N.; Chang, Y. C.; Brown, K. C. Novel ligands for cancer diagnosis: Selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp. Hematol., 2006, 34, 443-452.
158. Nishimura, S.; Takahashi, S.; Kamikatahira, H.; Kuroki, Y.; Jaalouk, D. E.; O'Brien, S.; Koivunen, E.; Arap, W.; Pasqualini, R.; Nakayama, H.; Kuniyasu, A. Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells. J. Biol. Chem., 2008, 283, 11752-11762.
159. Szecsi, P. B.; Riise, E.; Roslund, L. B.; Engberg, J.; Turesson, I.; Buhl, L.; Schafer-Nielsen, C. Identification of patient-specific peptides for detection of M-proteins and myeloma cells. Br. J. Haematol., 1999, 107, 357-364.
160. Wu, P.; Leinonen, J.; Koivunen, E.; Lankinen, H.; Stenman, U. H. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem., 2000, 267, 6212-6220.
161. Romanov, V. I.; Durand, D. B.; Petrenko, V. A. Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion. Prostate, 2001, 47, 239-251.
162. Huang, C. H.; Liu, X. Y.; Rehemtulla, A.; Lawrence, T. S. Identification of peptides that bind to irradiated pancreatic tumor cells. Int. J. Radiat. Oncol. Biol. Physics, 2005, 62, 1497-1503.
163. Zitzmann, S.; Mier, W.; Schad, A.; Kinscherf, R.; Askoxylakis, V.; Kramer, S.; Altmann, A.; Eisenhut, M.; Haberkorn, U. New prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin. Cancer Res., 2005, 11, 139-146.
164. Newton, J. R.; Kelly, K. A.; Mahmood, U.; Weissleder, R.; Deutscher, S. L. In vivo selection of phage for the optical Imaging of PC-3 human prostate carcinoma in mice. Neoplasia, 2006, 8, 772-780.
165. Zhang, J. B.; Spring, H.; Schwab, M. Neuroblastoma tumor cellbinding peptides identified through random peptide phage display. Cancer Lett., 2001, 171, 153-164.
166. Rasmussen, U. B.; Schreiber, V.; Schultz, H.; Mischler, F.; Schughart, K. Tumor cell-targeting by phage-displayed peptides. Cancer Gene Ther., 2002, 9, 606-612.
167. Hong, F. D.; Clayman, G. L. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res., 2000, 60, 6551-6556.
168. Ivanenkov, V. V.; Felici, F.; Menon, A. G. Targeted delivery of multivalent phage display vectors into mammalian cells. Biochimica Et Biophysica Acta-Mol. Cell Res., 1999, 1448, 463-472.
169. Lee, T. Y.; Wu, H. C.; Tseng, Y. L.; Lin, C. T. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res., 2004, 64, 8002-8008.
170. Sun, L.; Chu, T. W.; Wang, Y. & Wang, X. G. Radiolabeling and biodistribution of a nasopharyngeal carcinoma-targeting peptide identified by in vivo phage display. Acta. Biochimica. Et Biophysica Sinica, 2007, 39, 624-632.
171. Du, B.; Qian, M.; Zhou, Z.; Wang, P.; Wang, L.; Zhang, X.; Wu, M.; Zhang, P.; Mei, B. In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library. Biochem. Biophys. Res. Commun., 2006, 342, 956-962.
172. Jiang, Y. Q.; Wang, H. R.; Li, H. P.; Hao, H. J.; Zheng, Y. L.; Gu, J. Targeting of hepatoma cell and suppression of tumor growth by a novel 12mer peptide fused to superantigen TSST-1. Mol. Med., 2006, 12, 81-87.
173. Lo, A.; Lin, C. T.; Wu, H. C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Therap., 2008, 7, 579-589.
174. Kim, Y.; Lillo, A. M.; Steiniger, S. C.; Liu, Y.; Ballatore, C.; Anichini, A.; Mortarini, R.; Kaufmann, G. F.; Zhou, B.; Felding-Habermann, B.; Janda, K. D. Targeting heat shock proteins on cancer cells: Selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry, 2006, 45, 9434-9444.
175. Eriksson, F.; Culp, W. D.; Massey, R.; Egevad, L.; Garland, D.; Persson, M. A.; Pisa, P. Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol. Immunother., 2007, 56, 677-687.
176. Hu, S. J.; Guo, X.; Xie, H.; Du, Y.; Pan, Y.; Shi, Y.; Wang, J.; Hong, L.; Han, S.; Zhang, D.; Huang, D.; Zhang, K.; Bai, F.; Jiang, H.; Zhai, H.; Nie, Y.; Wu, K.; Fan, D. Phage display selection of peptides that inhibit metastasis ability of gastric cancer cells with high liver-metastatic potential. Biochem. Biophys. Res. Commun., 2006, 341, 964-972.
177. Bai, F. H.; Liang, J.; Wang, J.; Shi, Y.; Zhang, K.; Liang, S.; Hong, L.; Zhai, H.; Lu, Y.; Han, Y.; Yin, F.; Wu, K.; Fan, D. Inhibitory effec ts of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer. J. Mol. Med., 2007, 85, 169-180.
178. Akita, N.; Maruta, F.; Seymour, L. W.; Kerr, D. J.; Parker, A. L.; Asai, T.; Oku, N.; Nakayama, J.; Miyagawa, S. Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci., 2006, 97, 1075-1081.
179. Zhi, M.; Wu, K. C.; Dong, L.; Hao, Z. M.; Deng, T. Z.; Hong, L.; Liang, S. H.; Zhao, P. T.; Qiao, T. D.; Wang, Y.; Xu, X.; Fan, D. M. Characterization of a specific phage-displayed peptide binding to vasculature of human gastric cancer. Cancer Biol. Ther., 2004, 3, 1232-1235.
180. Kelly, K. A.; Jones, D. A. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia, 2003, 5, 437-444.
181. Hsiung, P. L.; Hardy, J.; Friedland, S.; Soetikno, R.; Du, C. B.; Wu, A. P.; Sahbaie, P.; Crawford, J. M.; Lowe, A. W.; Contag, C. H.; Wang, T. D. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat. Med., 2008, 14, 585-585.
182. Kubo, N.; Akita N.; Shimizu, A.; Kitahara, H.; Parker, A. L.; Miyagawa, S. Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. J. Drug Target., 2008, 16, 396-404.
183. Zhang, Y. D.; Chen, J.; Zhang, Y.; Hu, Z.; Hu, D.; Pan, Y.; Ou, S.; Liu, G.; Yin, X.; Zhao, J.; Ren, L.; Wang, J. Panning and identification of a colon tumor binding peptide from a phage display peptide library. J. Biomol. Screening, 2007, 12, 429-435.
184. Samoylova, T. I.; Petrenko, V. A.; Morrison, N. E.; Globa, L. P.; Baker, H. J.; Cox, N. R. Phage probes for malignant glial cells. Mol. Cancer Ther., 2003, 2, 1129-1137.
185. Spear, M. A.; Breakefield, X. O.; Beltzer, J.; Schuback, D.; Weissleder, R.; Pardo, F. S.; Ladner, R. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Ther., 2001, 8, 506-511.
186. Robinson, P.; Stuber, D.; Deryckere, F.; Tedbury, P.; Lagrange, M.; Orfanoudakis, G. Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines. J. Mol. Recog., 2005, 18, 175-182.
187. Bockmann, M.; Drosten, M.; Putzer, B. M. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J. Gene Med., 2005, 7, 179-188.
188. Bockmann, M.; Hilken, G.; Schmidt, A.; Cranston, A. N.; Tannapfel, A.; Drosten, M.; Frilling, A.; Ponder, B. A.; Putzer, B. M. Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection. Human Gene Ther., 2005, 16, 1267-1275.
189. Jager, S.; Jahnke, A.; Wilmes, T.; Adebahr, S.; Vogtle, F. N.; Delima-Hahn, E.; Pfeifer, D.; Berg, T.; Lubbert, M.; Trepel, M. Leukemia targeting ligands isolated from phage display peptide libraries. Leukemia, 2007, 21, 411-420.
190. Porkka, K.; Laakkonen, P.; Hoffman, J. A.; Bernasconi, M.; Ruoslahti, E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Nat. Acad. Sci. U. S. A., 2002, 99, 7444-7449.
191. Oyama, T.; Sykes, K. F.; Samli, K. N.; Minna, J. D.; Johnston, S. A.; Brown, K. C. Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett., 2003, 202, 219-230.
192. Oyama, T.; Rombel, I. T.; Samli, K. N.; Zhou, X.; Brown, K. C. Isolation of multiple cell-binding ligands from different phage displayed-peptide libraries. Biosensors Bioelect., 2006, 21, 1867-1875.
193. Zang, L. Q.; Shi, L.; Guo, J.; Pan, Q.; Wu, W.; Pan X.; Wang, J. Screening and Identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library. Cancer Lett., 2009, 281, 64-70.
194. Chang, D. K.; Lin, C. T.; Wu, C. H.; Wu, H. C. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One, 2009, 4, e4171.
195. Han, Z.; Fu, A.; Wang, H.; Diaz, R.; Geng, L.; Onishko, H.; Hallahan, D. E. Noninvasive assessment of cancer response to therapy. Nat. Med., 2008, 14, 343-349.
196. Lee, S. M.; Lee, E. J.; Hong, H. Y.; Kwon, M. K.; Kwon, T. H, Choi, J. Y.; Park, R. W.; Kwon, T. G.; Yoo, E. S.; Yoon, G. S.; Kim, I. S.; Ruoslahti, E.; Lee, B. H. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol. Cancer Res., 2007, 5, 11-19.
197. Kelly, K. A.; Bardeesy, N.; Anbazhagan, R.; Gurumurthy, S.; Berger, J.; Alencar, H.; Depinho, R. A.; Mahmood, U.; Weissleder, R. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med., 2008, 5, 657-668.
198. Chang, D. K.; Chiu, C. Y.; Kuo, S. Y.; Lin, W. C.; Lo, A.; Wang, Y. P.; Li, P. C.; Wu, H. C. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem., 2009, 284, 12905-12916.
199. van Tellingen, O.; Yetkin-Arik, B.; de Gooijer, MC.; Wesseling, P.; Wurdinger, T.; de Vries, H. E. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Update, 2015, 19, 1-12.
200. Deeken, J. F.; Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res., 2007, 13, 1663-1674.
201. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. Cancer J. Clin., 2014, 64, 9-29.
202. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P. L.; Burkhard, C.; Schuler, D.; Probst-Hensch, N. M.; Maiorka, P. C.; Baeza, N.; Pisani, P.; Yonekawa, Y.; Yasargil, M. G.; Lutolf, U. M.; Kleihues, P. Genetic pathways to glioblastoma: A population-based study. Cancer Res., 2004, 64, 6892-6899.
203. Begley, D. J.; Brightman, M. W. Structural and functional aspects of the blood-brain barrier. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des Recherches Pharmaceutiques, 2003, 61, 39-78.
204. Schinkel, A. H.; Wagenaar, E.; Mol, C. A.; van Deemter, L. Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 1996, 97, 2517-2524.
205. Gilbertson, R. J.; Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer, 2007, 7, 733-736.
206. Vannucci, S. J.; Maher, F.; Simpson, I. A. Glucose transporter proteins in brain: Delivery of glucose to neurons and glia. Glia, 1997, 21, 2-21.
207. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmaco. Exp. Therap., 2008, 324, 1064-1072.
208. Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J. P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol., 2008, 155, 185-197.
209. Drappatz, J.; Brenner, A.; Wong, E. T.; Eichler, A.; Schiff, D.; Groves, M. D.; Mikkelsen, T.; Rosenfeld, S.; Sarantopoulos, J.; Meyers, C. A.; Fielding, R. M.; Elian, K.; Wang, X.; Lawrence, B.; Shing, M.; Kelsey, S.; Castaigne, J. P.; Wen, P. Y. Phase I study of GRN1005 in recurrent malignant glioma. Clin. Cancer Res., 2013, 19, 1567-1576.
210. Xin, H.; Jiang, X.; Gu, J.; Sha, X.; Chen, L.; Law, K.; Chen, Y.; Wang, X.; Jiang, Y.; Fang, X. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials, 2011, 32, 4293-4305.
211. Moos, T.; Morgan, E. H. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol., 2000, 20, 77-95.
212. Zhang, P.; Hu, L.; Yin, Q.; Feng, L.; Li, Y. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential bloodbrain barrier penetration and glioma targeting therapy. Mol. Pharm., 2012, 9, 1590-1598.
213. MacDonald, T. J.; Taga, T.; Shimada, H.; Tabrizi, P.; Zlokovic, B. V.; Cheresh, D. A.; Laug, W. E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an [alpha]v Integrin antagonist. Neurosurgery, 2001, 48, 151-157.
214. Lee, J. H.; Engler, J. A.; Collawn, J. F.; Moore, B. A. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. J. Biochem., 2001, 268, 2004-2012.
215. Han, L.; Huang, R.; Liu, S.; Huang, S.; Jiang, C. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol. Pharm., 2010, 7, 2156-2165.
216. Son, S.; Hwang do, W.; Singha, K.; Jeong, J. H.; Park, T. G.; Lee, D. S.; Kim, W. J. RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain. J. Control. Release, 2011, 155, 18-25.
217. Maecke, H. R.; Hofmann, M.; Haberkorn, U. Ga-68-labeled peptides in tumor imaging. J. Nuclear Med., 2005, 46, 172s-178s.
218. Okarvi, S. M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur. J. Nuclear Med., 2001, 28, 929-938.
219. Nitin, N.; LaConte, L. E. W.; Zurkiya, O.; Hu, X.; Bao, G. Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J. Biol. Inorganic Chem., 2004, 9, 706-712.
220. Lee, H. Y.; Li, Z.; Chen, K.; Hsu, A. R.; Xu, C.; Xie, J.; Sun, S.; Chen, X. PET/MRI dual-modality tumor imaging using arginineglycine-aspartic (RGD)-Conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med., 2008, 49, 1371-1379.
221. Chan, W. C. W.; Nie, S. M. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science, 1998, 281, 2016-2018.
222. Bruchez, M.; Moronne, M.; Gin, P.; Weiss, S.; Alivisatos, A. P. Semiconductor nanocrystals as fluorescent biological labels. Science, 1998, 281, 2013-2016.
223. Gao, X. H.; Cui, Y. Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S. M. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 2004, 22, 969-976.
224. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angewandte Chemie-Int. Edition, 1998, 37, 2755-2794.
225. Cai, W. B.; Shin, D. W.; Chen, K.; Gheysens, O.; Cao, Q.; Wang, S. X.; Gambhir, S. S.; Chen, X. Peptide-labeed near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett., 2006, 6, 669-676.
226. Chen, Y.; Foss, C. A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J. J.; Castanares, M.; Lupold, S. E.; Babich, J. W.; Mease, R. C.; Pomper, M. G. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J. Med. Chem., 2008, 51, 7933-7943.
227. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D. W. Cordon, C. C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 1997, 3, 81-85.
228. Sweat, S. D.; Pacelli, A.; Murphy, G. P.; Bostwick, D. G. Prostatespecific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 1998, 52, 637-640.
229. Ross, J. S.; Sheehan, C. E.; Fisher, H. A.; Kaufman, R. P. Jr, Kaur, P.; Gray, K.; Webb, I.; Gray, G. S.; Mosher, R.; Kallakury, B. V. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res., 2003, 9, 6357-6362.
230. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumorassociated neovasculature. Cancer Res., 1999, 59, 3192-3198.
231. Carter, R. E.; Feldman, A. R.; Coyle, J. T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Nat. Acad. Sci. U. S. A., 1996, 93, 749-753.
232. Pinto, J. T.; Suffoletto, B. P.; Berzin, T. M.; Qiao, C. H.; Lin, S.; Tong, W. P.; May, F.; Mukherjee, B.; Heston, W. D. Prostatespecific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 1996, 2, 1445-1451.
233. Barinka, C.; Byun, Y.; Dusich, C. L.; Banerjee, S. R.; Chen, Y.; Castanares, M.; Kozikowski, A. P.; Mease, R. C.; Pomper, M. G.; Lubkowski, J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J. Med. Chem., 2008, 51, 7737-7743.
234. Mease, R. C.; Dusich, C. L.; Foss, C. A.; Ravert, H. T.; Dannals, R. F.; Seidel, J.; Prideaux, A.; Fox, J. J.; Sgouros, G.; Kozikowski, A. P.; Pomper, M. G. N-[N-[(S)-1, 3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin. Cancer Res., 2008, 14, 3036-3043.
235. Foss, C. A.; Mease, R. C.; Fan, H.; Wang, Y.; Ravert, H. T.; Dannals, R. F.; Olszewski, R. T.; Heston, W. D.; Kozikowski, A. P.; Pomper, M. G. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res., 2005, 11, 4022-4028.
236. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res., 2009, 69, 6932-6940.
237. Hoffman, J. M.; Gambhir, S. S. Molecular imaging: The vision and opportunity for radiology in the future. Radiology, 2007, 244, 39-47.
238. Elias, D. R.; Thorek, D. L. J.; Chen, A. K.; Czupryna, J.; Tsourkas, A. In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomarkers, 2008, 4, 287-305.
239. Zhang, P.; Cheetham, A. G.; Lock, L. L.; Li, Y.; Cui, H. Activatable nanoprobes for biomolecular detection. Curr. Opin. Biotechnol., 2015, 34C, 171-179.
240. Lee, S.; Xie, J.; Chen, X. Y. Activatable molecular probes for cancer imaging. Curr. Topics Med. Chem., 2010, 10, 1135-1144.
241. Pham, W.; Choi, Y. D.; Weissleder, R.; Tung, C. H. Developing a peptide-based near-infrared molecular probe for protease sensing. Bioconjugate Chem., 2004, 15, 1403-1407.
242. Lock, L. L.; Cheetham, A. G.; Zhang, P. C.; Cui, H. G. Design and construction of supramolecular nanobeacons for enzyme detection. ACS Nano, 2013, 7, 4924-4932.
243. Duncan, R.; Cable, H. C.; Lloyd, J. B.; Rejmanova, P.; Kopecek, J. Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side-chains in poly N-(2-hydroypropyl) methacrylamide co-polymers to promote efficient degradation by lysosomal-enzymes. Makromolekulare Chemie-Macromolecular Chem. Phys., 1983, 184, 1997-2008.
244. Jedeszko, C.; Sloane, B. F. Cysteine cathepsins in human cancer. Biological Chem., 2004, 385, 1017-1027.
245. Janib, S. M.; Moses, A. S.; MacKay, J. A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev., 2010, 62, 1052-1063.
246. Xie, J.; Lee, S.; Chen, X. Y. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Revi., 2010, 62, 1064-1079.
247. Xia, Y. N.; Li, W.; Cobley, C. M.; Chen, J.; Xia, X.; Zhang, Q.; Yang, M.; Cho, E. C.; Brown, P. K. Gold nanocages: from synthesis to theranostic applications. Acc. Chem. Res., 2011, 44, 914-924.
248. Bardhan, R.; Lal, S.; Joshi, A.; Halas, N. J. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc. Chem. Res., 2011, 44, 936-946.
249. Al-Jamal, W. T.; Kostarelos, K. Liposomes: From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res., 2011, 44, 1094-1104.
250. Ho, D.; Sun, X. L.; Sun, S. H. Monodisperse magnetic nanoparticles for theranostic applications. Acc. Chem. Res., 2011, 44, 875-882.
251. Yang, K.; Feng, L. Z.; Shi, X. Z.; Liu, Z. Nano-graphene in biomedicine: theranostic applications. Chem. Soc. Rev., 2013, 42, 530-547.
252. Lee, J. E.; Lee, N.; Kim, T.; Kim, J.; Hyeon, T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc. Chem. Res., 2011, 44, 893-902.